It is not suitable for type 1 diabetes, diabetic ketoacidosis, or as firstline monotherapy when diet and exercise alone have not been evaluated
That being said only 4.1 % of patients stopped the 4mg dose which is less than the placebo arm
For children and young people with type 1 diabetes (n=400, aged 7 to 25 years in Bangladesh and Tanzania), long-acting analogue insulin glargine was associated with less time spent in dangerous hypoglycemia and fewer nighttime low blood sugar events than older human insulin but these benefits didnt emerge until a year into the randomised clinical trial
[DOI] [PubMed] [Google Scholar] 43.Robert A., Nezamis J.E., Lancaster C., Davis J.P., Field S.O., Hanchar A.J
As a result, "primary care [doctors] are reticent to try them because many times they're not covered by insurance and should be" for older patients, Dr